Our findings firstly identify that circ_0009910 is significantly upregulated in AML bone marrow samples and might serve as a novel outcome biomarker for AML. Both circ_0009910 and miR-20a-5p may be potential therapeutic targets for future AML treatment.
Silencing of circ_0009910 inhibits acute myeloid leukemia cell growth through increasing miR-20a-5p.